Professional Documents
Culture Documents
Country Profiles: Annex 2
Country Profiles: Annex 2
Country Profiles: Annex 2
Country
profiles
Afghanistan Population 2013 31 million
High TB burden
Prevalence
MDR-TB cases among notified 400
pulmonary TB cases 820 (560–1 100) 460 (300–610)
200
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 14 277 1 154 1990 1995 2000 2005 2010
Incidence
150
50
Among 30 507 new and relapse cases:
3 454 (11%) cases aged under 15 years; male:female ratio: 0.7 0
TB/HIV 2013
6
Number (%)
TB patients with known HIV status 8 247 (26) 4
HIV-positive people screened for TB 100 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
80
HIV-positive TB cases, all types, registered in 2012
RR-/MDR-TB cases started on second-line treatment in 2011 29 60
% Funded domestically 8%
10
% Funded internationally 57%
% Unfunded 35%
5
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 125
Bangladesh Population 2013 157 million
High TB burden | High MDR-TB burden
Prevalence
500
MDR-TB cases among notified
pulmonary TB cases 2 100 (1 000–3 700) 2 600 (2 200–3 200)
250
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 105 539 2 869 1990 1995 2000 2005 2010
Incidence
Total cases notified 190 891
100
TB/HIV 2013
60
Number (%)
TB patients with known HIV status 2 067 (1) 40
HIV-positive people screened for TB 607 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
100
HIV-positive TB cases, all types, registered in 2012 81
RR-/MDR-TB cases started on second-line treatment in 2011 68 80
XDR-TB cases started on second-line treatment in 2011 100
60
Laboratories 2013
Smear (per 100 000 population) 0.7 40
Culture (per 5 million population) <0.1 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) <0.1 New Retreatment New and relapse
Sites performing Xpert MTB/RIF 26 Retreatment excluding relapse HIV-positive
RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in and outside country
% Funded domestically 5%
40
% Funded internationally 33%
% Unfunded 62%
20
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in
consultation with countries.
a Ranges represent uncertainty intervals. Estimates of TB disease burden have not been approved
0
by the national TB programme in Bangladesh and a joint reassessment will be undertaken 2010 2011 2012 2013 2014
following the completion of the prevalence survey planned for 2015.
b Includes cases with unknown previous TB treatment history Funded domestically Funded internationally Unfunded
126 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
Brazil Population 2013 200 million
High TB burden | High HIV burden
Prevalence
MDR-TB cases among notified 100
pulmonary TB cases 840 (600–1 100) 940 (710–1 200)
50
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 41 885 3 613 1990 1995 2000 2005 2010
Incidence
Total cases notified 83 310 50
25
Among 76 020 new and relapse cases:
2 647 (3%) cases aged under 15 years; male:female ratio: 2.0 0
TB/HIV 2013
6000
Number (%)
TB patients with known HIV status 54 213 (65) 4000
HIV-positive people screened for TB 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
80
20
Laboratories 2013
Smear (per 100 000 population) 1.5 0
Culture (per 5 million population) 8.6 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 1.0 New Retreatment New and relapse
Retreatment excluding relapse HIV-positive
Sites performing Xpert MTB/RIF 0 RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
80
% Funded domestically 87%
% Funded internationally 2% 60
% Unfunded 12% 40
20
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 127
Cambodia Population 2013 15 million
High TB burden | High HIV burden
Prevalence
1500
MDR-TB cases among notified
pulmonary TB cases 320 (160–580) 180 (68–370) 1000
500
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 14 082 389 1990 1995 2000 2005 2010
Incidence
400
Total cases notified 39 055
200
Among 14 083 new cases:
64 (<1%) cases aged under 15 years; male:female ratio: 1.2 0
HIV-positive people screened for TB 1 241 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
HIV-positive people provided with IPT 1 343 HIV-positive TB patients on CPT on ART
90
HIV-positive TB cases, all types, registered in 2012
RR-/MDR-TB cases started on second-line treatment in 2011 86 80
XDR-TB cases started on second-line treatment in 2011
70
Laboratories 2013
Smear (per 100 000 population) 1.4 60
Culture (per 5 million population) 1.3 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 0.3 New Retreatment New and relapse
Sites performing Xpert MTB/RIF 10 Retreatment excluding relapse HIV-positive
RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? No
% Funded domestically 4% 30
10
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
128 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
China Population 2013 1 386 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
150
Pulmonary, bacteriologically confirmed 275 915 28 025 1990 1995 2000 2005 2010
Incidence
100
Total cases notified 855 241
50
Among 847 176 new and relapse cases:
4 830 (<1%) cases aged under 15 years; male:female ratio: 2.2 0
HIV-positive people screened for TB 358 345 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
80
20
Laboratories 2013
Smear (per 100 000 population) 0.2 0
Culture (per 5 million population) 4.6 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 0.9 New Retreatment New and relapse
Sites performing Xpert MTB/RIF 160 Retreatment excluding relapse HIV-positive
RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
% Funded internationally 3%
200
% Unfunded 19%
100
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 129
Democratic Republic of the Congo Population 2013 68 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
MDR-TB cases among notified 600
pulmonary TB cases 2 200 (9–4 700) 900 (14–2 000)
300
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 71 526 3 981 1990 1995 2000 2005 2010
Incidence
Total cases notified 113 603 200
100
Among 71 526 new cases:
3 086 (4%) cases aged under 15 years; male:female ratio: 1.3
0
Number (%)
4000
TB patients with known HIV status 49 816 (44)
HIV-positive TB patients 6 984 (14)
2000
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 866 (70)
HIV-positive TB patients on antiretroviral therapy (ART) 3 371 (48) 0
HIV-positive people screened for TB 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
HIV-positive people provided with IPT HIV-positive TB patients on CPT on ART
Laboratories 2013 40
% Funded domestically 3% 60
20
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
130 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
Ethiopia Population 2013 94 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
400
MDR-TB cases among notified
pulmonary TB cases 1 400 (800–2 500)
200
Incidence
Total cases notified 131 677
200
8000
Number (%)
6000
TB patients with known HIV status 93 356 (71)
HIV-positive TB patients 10 374 (11) 4000
% Funded domestically 7%
100
% Funded internationally 30%
% Unfunded 63%
50
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in
consultation with countries. 0
a Ranges represent uncertainty intervals. Estimates of TB disease burden for Ethiopia are
2010 2011 2012 2013 2014
provisional pending a joint review by WHO and the MOH in early 2015.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 131
India Population 2013 1 252 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
300
MDR-TB cases among notified
pulmonary TB cases 20 000 (17 000–24 000) 41 000 (30 000–52 000) 200
100
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 621 762 102 660 1990 1995 2000 2005 2010
Incidence
150
Total cases notified 1 415 617
100
TB/HIV 2013
30 000
Number (%)
TB patients with known HIV status 887 903 (63) 20 000
HIV-positive people screened for TB 1 063 644 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
80
20
Laboratories 2013
Smear (per 100 000 population) 1.0 0
Culture (per 5 million population) 0.2 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 0.2 New Retreatment New and relapse
Sites performing Xpert MTB/RIF 54 Retreatment excluding relapse HIV-positive
RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
132 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
Indonesia Population 2013 250 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
500
MDR-TB cases among notified
pulmonary TB cases 5 700 (4 200–7 500) 1 100 (770–1 600)
250
Pulmonary, bacteriologically confirmed 196 310 6 406 1990 1995 2000 2005 2010
Incidence
150
Total cases notified 327 103
100
Number (%)
TB patients with known HIV status 7 631 (2)
1000
HIV-positive TB patients 1 599 (21)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 477 (30)
HIV-positive TB patients on antiretroviral therapy (ART) 332 (21) 0
HIV-positive people screened for TB 22 190 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
80
HIV-positive TB cases, all types, registered in 2012 49
RR-/MDR-TB cases started on second-line treatment in 2011 60 60
XDR-TB cases started on second-line treatment in 2011 50
40
Laboratories 2013
Smear (per 100 000 population) 2.2 20
Culture (per 5 million population) 0.4 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 0.2 New Retreatment New and relapse
Sites performing Xpert MTB/RIF 23 Retreatment excluding relapse HIV-positive
RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 133
Kenya Population 2013 44 million
High TB burden | High HIV burden
Prevalence
MDR-TB cases among notified
pulmonary TB cases 1 700 (7–3 700) 1 100 (17–2 300) 200
Pulmonary, bacteriologically confirmed 34 686 4 632 1990 1995 2000 2005 2010
Incidence
200
Total cases notified 89 796
100
Among 74 335 new cases:
4 383 (6%) cases aged under 15 years; male:female ratio: 1.4 0
HIV-positive people screened for TB 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
80
Laboratories 2013 20
20
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
134 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
Mozambique Population 2013 26 million
High TB burden | High HIV burden
Prevalence
1000
MDR-TB cases among notified
pulmonary TB cases 1 500 (950–2 100) 830 (0–1 900)
500
Pulmonary, bacteriologically confirmed 23 115 2 081 1990 1995 2000 2005 2010
Incidence
Total cases notified 56 220 400
TB/HIV 2013
Number (%) 30 000
20 000
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 27 624 (97)
HIV-positive TB patients on antiretroviral therapy (ART) 20 449 (72)
10 000
HIV-positive people screened for TB
HIV-positive people provided with IPT 48 188
0
Treatment success rate (%)
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
New cases registered in 2012 87
HIV-positive TB patients on CPT on ART
Previously treated cases registered in 2012
HIV-positive TB cases, all types, registered in 2012
RR-/MDR-TB cases started on second-line treatment in 2011 31 100
80
Laboratories 2013 60
Smear (per 100 000 population) 1.3
40
Culture (per 5 million population) 0.6
Drug susceptibility testing (per 5 million population) 0.4 20
Sites performing Xpert MTB/RIF 14
0
Is second-line drug susceptibility testing available? Yes, outside country
1995 1997 1999 2001 2003 2005 2007 2009 2011
Financing TB control 2014 New Retreatment HIV-positive
RR-/MDR-TB XDR-TB
National TB programme budget (US$ millions) 19
% Funded domestically
% Funded internationally 22% 40
% Unfunded 78%
Total budget (US$ millions)
30
20
10
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 135
Myanmar Population 2013 53 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
1000
MDR-TB cases among notified
pulmonary TB cases 5 700 (3 500–7 700) 3 300 (1 800–4 800)
500
Incidence
300
Total cases notified 142 162
200
TB/HIV 2013
Number (%) 6000
4000
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 826 (89)
3000
HIV-positive TB patients on antiretroviral therapy (ART) 3 987 (74)
HIV-positive people screened for TB 45 337 2000
0
Treatment success rate (%)
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
New cases registered in 2012 89
HIV-positive TB patients on CPT on ART
Previously treated cases registered in 2012 70
HIV-positive TB cases, all types, registered in 2012
RR-/MDR-TB cases started on second-line treatment in 2011 71 100
Laboratories 2013 80
% Unfunded 35%
Total budget (US$ millions)
30
20
10
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in
consultation with countries. 0
a Ranges represent uncertainty intervals.
2010 2011 2012 2013 2014
b Case notifications were updated after TB burden estimates had already been produced.
c Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
136 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
Nigeria Population 2013 174 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
MDR-TB cases among notified 200
pulmonary TB cases 2 500 (1 800–3 500) 1 200 (860–1 600)
100
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 52 811 2 828 1990 1995 2000 2005 2010
Incidence
300
Total cases notified 100 401
200
15 000
TB/HIV 2013
Number of patients
Number (%)
10 000
TB patients with known HIV status 88 317 (88)
HIV-positive TB patients 19 423 (22) 5000
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 16 948 (87)
HIV-positive TB patients on antiretroviral therapy (ART) 12 923 (67) 0
HIV-positive people screened for TB 435 216 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
HIV-positive people provided with IPT 7 973 HIV-positive TB patients on CPT on ART
Laboratories 2013 40
40
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 137
Pakistan Population 2013 182 million
High TB burden | High MDR-TB burden
Prevalence
400
MDR-TB cases among notified
pulmonary TB cases 9 900 (6 400–13 000) 3 100 (2 200–4 000)
200
Pulmonary, bacteriologically confirmed 111 682 6 303 1990 1995 2000 2005 2010
Incidence
200
Total cases notified 298 446
100
Among 282 607 new cases:
28 113 (10%) cases aged under 15 years; male:female ratio: 1.0 0
Number (%)
20
TB patients with known HIV status 8 306 (3)
HIV-positive TB patients 36 (<1) 10
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
HIV-positive TB patients on antiretroviral therapy (ART) 0
HIV-positive people screened for TB 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
HIV-positive people provided with IPT HIV-positive TB patients on CPT on ART
80
HIV-positive TB cases, all types, registered in 2012
RR-/MDR-TB cases started on second-line treatment in 2011 70 60
Laboratories 2013 20
Smear (per 100 000 population) 0.8
0
Culture (per 5 million population) 0.3
1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 0.2
New Retreatment HIV-positive
Sites performing Xpert MTB/RIF 32 RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
% Funded domestically
80
% Funded internationally 30%
60
% Unfunded 70%
40
20
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
138 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
Philippines Population 2013 98 million
High TB burden | High MDR-TB burden
Prevalence
MDR-TB cases among notified
pulmonary TB cases 4 400 (3 100–6 000) 4 100 (3 000–5 500) 500
Pulmonary, bacteriologically confirmed 97 353 4 669 1990 1995 2000 2005 2010
Incidence
Total cases notified 244 392
200
TB/HIV 2013
Number of patients
20
Number (%)
TB patients with known HIV status 5 034 (2)
10
HIV-positive TB patients 26 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
HIV-positive TB patients on antiretroviral therapy (ART) 0 J
HIV-positive people screened for TB 3 006 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
HIV-positive people provided with IPT HIV-positive TB patients on CPT on ART
80
HIV-positive TB cases, all types, registered in 2012
RR-/MDR-TB cases started on second-line treatment in 2011 41 60
Laboratories 2013 20
Smear (per 100 000 population) 2.6
0
Culture (per 5 million population) 0.9
1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 0.2
New Retreatment HIV-positive
Sites performing Xpert MTB/RIF 16 RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
40
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 139
Russian Federation Population 2013 143 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
200
MDR-TB cases among notified
pulmonary TB cases 16 000 (11 000–20 000) 25 000 (20 000–30 000)
100
Pulmonary, bacteriologically confirmed 37 779 7 866 1990 1995 2000 2005 2010
Incidence
Total cases notified 142 533
50
TB/HIV 2013
Number (%) 4000
TB patients with known HIV statusc 69 724
HIV-positive TB patients 4 990 2000
HIV-positive people screened for TB 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
60
HIV-positive TB cases, all types, registered in 2012
RR-/MDR-TB cases started on second-line treatment in 2011 37 40
XDR-TB cases started on second-line treatment in 2011
20
Laboratories 2013
Smear (per 100 000 population) 3.7 0
Culture (per 5 million population) 11.6 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 7.6 New Retreatment New and relapse
Sites performing Xpert MTB/RIF 72 Retreatment excluding relapse HIV-positive
RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
% Funded internationally
1000
% Unfunded 0%
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in
500
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history.
c The reported number of TB patients with known HIV status is for new TB patients in the civilian
0
2010 2011 2012 2013 2014
sector only. It was not possible to calculate the percentage of all TB patients with known HIV
status. Funded domestically Funded internationally Unfunded
140 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
South Africa Population 2013 53 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
MDR-TB cases among notified
pulmonary TB cases 4 600 (3 600–5 900) 2 200 (1 800–2 700) 500
Pulmonary, bacteriologically confirmed 109 630 7 751 1990 1995 2000 2005 2010
Incidence
Total cases notified 328 896 500
250
Among 312 380 new and relapse cases:
36 671 (12%) cases aged under 15 years; male:female ratio: 1.2 0
Number (%)
100 000
TB patients with known HIV status 294 504 (90)
HIV-positive TB patients 181 736 (62) 50 000
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 146 973 (81)
HIV-positive TB patients on antiretroviral therapy (ART) 120 298 (66) 0
HIV-positive people screened for TB 961 967 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
80
20
Laboratories 2013
Smear (per 100 000 population) 0.4 0
Culture (per 5 million population) 1.4 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 1.4 New Retreatment New and relapse
Retreatment excluding relapse HIV-positive
Sites performing Xpert MTB/RIF 207 RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
400
% Funded domestically 84%
% Funded internationally 16% 300
% Unfunded 0% 200
100
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 141
Thailand Population 2013 67 million
High TB burden | High HIV burden
Prevalence
MDR-TB cases among notified 200
pulmonary TB cases 1 000 (730–1 500) 880 (640–1 200)
100
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 32 887 1 802 1990 1995 2000 2005 2010
Incidence
100
Total cases notified 66 415
50
Reported cases of RR-/MDR-TB 2013
New Retreatment Totalb
0
Cases tested for RR-/MDR-TB 3 246 (10%) 540 (12%) 3 866
1990 1995 2000 2005 2010
Laboratory-confirmed RR-/MDR-TB cases 230
Notified (new and relapse) Incidence
Patients started on MDR-TB treatment 230 Incidence (HIV+TB only)
TB/HIV 2013
10 000
Number (%)
TB patients with known HIV status 54 991 (83) 8000
Number of patients
80
Laboratories 2013
Smear (per 100 000 population) 1.6
60
Culture (per 5 million population) 4.8
Drug susceptibility testing (per 5 million population) 1.3
Sites performing Xpert MTB/RIF 14 40
Is second-line drug susceptibility testing available? Yes, in country 1995 1997 1999 2001 2003 2005 2007 2009 2011
% Unfunded 13%
Total budget (US$ millions)
40
30
20
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 10
consultation with countries.
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. 0
2010 2011 2012 2013 2014
c Data reported are only national level budgets for the Bureau of TB and the National Health
Security Office, and do not include provincial, local and private sector budgets. Funded domestically Funded internationally Unfunded
142 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
Uganda Population 2013 38 million
High TB burden | High HIV burden
Prevalence
600
MDR-TB cases among notified
pulmonary TB cases 540 (230–840) 490 (270–780)
300
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 25 442 1 312 1990 1995 2000 2005 2010
Incidence
500
Total cases notified 47 650
250
Among 25 408 new cases:
649 (3%) cases aged under 15 years; male:female ratio: 1.9 0
HIV-positive people screened for TB 675 373 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
80
HIV-positive TB cases, all types, registered in 2012
RR-/MDR-TB cases started on second-line treatment in 2011 77 60
XDR-TB cases started on second-line treatment in 2011
40
Laboratories 2013
Smear (per 100 000 population) 3.5 20
Culture (per 5 million population) 0.5 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 0.5 New Retreatment New and relapse
Sites performing Xpert MTB/RIF 37 Retreatment excluding relapse HIV-positive
RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
40
% Funded domestically 5%
% Funded internationally 14% 30
% Unfunded 81% 20
10
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 143
United Republic of Tanzania Population 2013 49 million
High TB burden | High HIV burden | High MDR-TB BUrden
Prevalence
MDR-TB cases among notified
pulmonary TB cases 530 (240–960) 86 (25–220) 200
Pulmonary, bacteriologically confirmed 24 565 1 101 1990 1995 2000 2005 2010
Incidence
Total cases notified 65 732
100
TB/HIV 2013
Number of patients
15 000
Number (%)
10 000
TB patients with known HIV status 54 504 (83)
HIV-positive TB patients 20 320 (37)
5 000
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 19 835 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 14 864 (73) 0
HIV-positive people screened for TB 457 901 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
HIV-positive people provided with IPT 166 HIV-positive TB patients on CPT on ART
Laboratories 2013
Smear (per 100 000 population) 1.9 60
Culture (per 5 million population) 0.5 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 0.1 New Retreatment New and relapse
Retreatment excluding relapse HIV-positive
Sites performing Xpert MTB/RIF 35 RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
20
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
144 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data
Viet Nam Population 2013 92 million
High TB burden | High HIV burden | High MDR-TB burden
Prevalence
MDR-TB cases among notified 500
pulmonary TB cases 3 000 (1 900–4 100) 2 100 (1 500–2 600)
250
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 50 607 7 059 1990 1995 2000 2005 2010
Incidence
Total cases notified 102 196
100
TB/HIV 2013
Number (%) 4000
TB patients with known HIV status 71 374 (70)
HIV-positive TB patients 4 438 (6) 2000
HIV-positive people screened for TB 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
80
20
Laboratories 2013
Smear (per 100 000 population) 1.1 0
Culture (per 5 million population) 1.3 1995 1997 1999 2001 2003 2005 2007 2009 2011
Drug susceptibility testing (per 5 million population) 0.1 New Retreatment New and relapse
Sites performing Xpert MTB/RIF 27 Retreatment excluding relapse HIV-positive
RR-/MDR-TB XDR-TB
Is second-line drug susceptibility testing available? Yes, in country
% Funded domestically 9% 60
20
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
Data for all years can be downloaded from www.who.int/tb/data Global Tuberculosis Report 2014 | 145
Zimbabwe Population 2013 14 million
High TB burden | High HIV burden
Prevalence
MDR-TB cases among notified 400
pulmonary TB cases 520 (270–900) 300 (66–820)
200
TB case notifications 2013
Newb Relapse 0
Pulmonary, bacteriologically confirmed 11 404 1 275 1990 1995 2000 2005 2010
Incidence
500
Total cases notified 35 278
250
Among 32 899 new and relapse cases:
2 567 (8%) cases aged under 15 years; male:female ratio: 1.3 0
30 000
TB/HIV 2013
Number of patients
Number (%)
20 000
TB patients with known HIV status 32 460 (92)
HIV-positive TB patients 22 442 (69) 10 000
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 17 267 (77)
HIV-positive TB patients on antiretroviral therapy (ART) 17 267 (77) 0
HIV-positive people screened for TB 323 431 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
HIV-positive people provided with IPT 10 926 HIV-positive TB patients on CPT on ART
Laboratories 2013 40
40
% Funded domestically 2%
% Funded internationally 43% 30
% Unfunded 55% 20
10
Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in 0
consultation with countries. 2010 2011 2012 2013 2014
a Ranges represent uncertainty intervals.
b Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
146 | Global Tuberculosis Report 2014 Data for all years can be downloaded from www.who.int/tb/data